ADMA Biologics (NASDAQ:ADMA – Get Free Report) and Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ADMA Biologics and Allarity Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 3 | 3 | 0 | 2.50 |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
ADMA Biologics presently has a consensus price target of $17.50, indicating a potential upside of 38.12%. Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 1,026.13%. Given Allarity Therapeutics’ higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than ADMA Biologics.
Profitability
This table compares ADMA Biologics and Allarity Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 35.14% | 42.56% | 26.96% |
| Allarity Therapeutics | N/A | -152.77% | -46.50% |
Insider and Institutional Ownership
75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by company insiders. Comparatively, 0.2% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares ADMA Biologics and Allarity Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $519.15 million | 5.47 | $146.93 million | $0.77 | 16.45 |
| Allarity Therapeutics | $320,000.00 | 45.25 | -$11.23 million | ($0.78) | -1.17 |
ADMA Biologics has higher revenue and earnings than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
ADMA Biologics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
Summary
ADMA Biologics beats Allarity Therapeutics on 11 of the 13 factors compared between the two stocks.
About ADMA Biologics
ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
